Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10595938 | Bioorganic & Medicinal Chemistry Letters | 2013 | 7 Pages |
Abstract
Efforts to address HIV infection have been highly successful, enabling chronic suppression of viral replication with once-daily regimens. More recent research into HCV therapeutics have also resulted in very promising clinical candidates. This Digest explores similarities and differences in the two fields and compares the chronology of drug discovery relative to the availability of enabling tools, and concludes that safe and convenient, once-daily regimens are likely to reach approval much more rapidly for HCV than was the case for HIV.
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
William J. Watkins, Manoj C. Desai,